Robert Roerich
Psychiatry · East Liverpool, OHNPI 1740212216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $908 and has fallen 98.0% since, to $18 in 2024.
Across 125 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$467
- AbbVie$438
- Lundbeck LLC$371
- Avanir Pharmaceuticals, Inc.$323
- Neurocrine Biosciences, Inc.$212
- Otsuka America Pharmaceutical, Inc.$177
- plus $868 from 14 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$2,80798%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $467 |
| AbbVie(2 entities) | 28 | $438 |
| Lundbeck LLC | 20 | $371 |
| Avanir Pharmaceuticals, Inc. | 11 | $323 |
| Neurocrine Biosciences, Inc. | 5 | $212 |
| Otsuka America Pharmaceutical, Inc. | 6 | $177 |
| Alkermes, Inc. | 6 | $175 |
| Almatica Pharma LLC | 8 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $136 |
| Sunovion Pharmaceuticals Inc. | 1 | $112 |
| Vanda Pharmaceuticals Inc. | 5 | $85 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Shire North American Group Inc | 2 | $30 |
| Orexo US, Inc. | 2 | $26 |
| Neos Therapeutics, LP | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,854 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in East Liverpool
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
- Tracey SkaleCincinnati$674K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.